Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

TOC Ariake Convention Hall

Apr 18, 2019 9:00 AM - Apr 19, 2019 5:40 PM

3-5-7 Ariake, , Koto-ku, Tokyo, 135-0063 Japan

DIA Asia 2019 International Conference

Asia, the future, changing with ICH


Click Here to View the program.

New DIA Asia Conference
DIA has held the DIA Asia New Drug Conference over 12 years in Japan, but this time, with the introduction of the new ICH framework, we will start a new conference series called “DIA Asia International Conference”. It has been decided to hold it under the cooperation of the various Asian countries; the first one is to be held in Tokyo and future ones will be held in other Asian counties in turn. In this conference, we will provide not only a program suitable for the new ICH scheme, but also a useful information exchange forum for the drug development in the new ara. New regulatory trends in various Asian countries will also be shared and provide an opportunity to discuss how counties in Asia can collaborate and provide breakthrough solutions for the patients.

Asia, the most important emerging region in the world
Asia has a huge population that accounts for 60% of the world, and economic growth is prominent, attracting global attention. Many countries has characteristic aging populations, and the increased medical needs have become similar to other developped regions. Asian countries are similar in many ways, such as culture, behavioral/language characteristics, ethnic factors, etc. In order to discuss common issues under such circumstances, forum where Asian people get together to share opinions would be very useful. On the other hand, the proportion of new products derived from Asia among medicines around the world, is still small, and the proportion of Asians in the clinical trials conducted worldwide is small, so that the Asia is expected to play a more important role in the global drug development in the future.

Asia, the future, changing with ICH
This year, the ICH has determined to allow multiple Asian regulators to join ICH as official members, drastically changing from 3 originating regions of the US, EU and Japan. These countries are all moving to a new era when they can introduce common pharmaceutical regulations and discuss issues on the same foundation. To meet the unmet medical needs, regulators are trying to accelerate the drug development, including the introduction of an expedited review process. Asian academies/companies also change the methods using a various new technologies to find a solution. It is becoming necessary to pay an effort to understand both the cutting-edge science and technology and changes in medical needs, flexibly responding to patient expectations.

Featured topics

Day 1: ICH Day

Day 2: Asia Conference Day


Want to learn more about DIA Asia 2019 International Conference? You've come to the right site!


Who should attend?

  • Clinical development
  • Medical affairs and market
  • Regulatory affairs
  • Academic organizations
  • Clinical study sites
  • Regulatory agencies
  • CROs and SMOs

Program Committee

  • Shinobu  Uzu, PhD
    Shinobu Uzu, PhD Senior Executive Director
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Ling  Su, PhD
    Ling Su, PhD Research Fellow
    Shenyang Pharmaceutical University, Yeehong Business School, China
  • Ari  Fujishiro
    Ari Fujishiro Senior Director, Regulatory Affairs Group, Asia Development Dept., R&D Division
    Daiichi Sankyo Co., Ltd., Japan
  • Shunsuke  Izuka
    Shunsuke Izuka Manager, Japan-Asia Clinical Development 1
    Astellas Pharma Inc., Japan
  • In-Jin  Jang, MD, PhD
    In-Jin Jang, MD, PhD Professor
    College of Medicine, Seoul National University, Korea, Republic of
  • Shun  Jin, MBA
    Shun Jin, MBA Head, Regulatory Affairs, APMA
    Sandoz Asia Pacific Pharmaceutical Pte., Ltd., Singapore
  • Kosuke  Mitsui, MBA, MSc, PMP
    Kosuke Mitsui, MBA, MSc, PMP President & General Manager
    Chugai Pharma Science (Beijing) Co., Ltd., China
  • Mamoru  Miyake, MS, RPh
    Mamoru Miyake, MS, RPh Director, Development Division
    Astellas Pharma China, China
  • Atsushi  Nonogaki, MSc
    Atsushi Nonogaki, MSc Manager, Regulatory Affairs Group, Asia Development Department, R&D Division
    Daiichi Sankyo Co., Ltd., Japan
  • Junko  Sato, PhD
    Junko Sato, PhD Associate Executive Director
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Shohko  Sekine
    Shohko Sekine Reviewer, Office of New Drug IV
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Crystal  Wang
    Crystal Wang Director of Development Division
    Chugai Pharma Taiwan Ltd., Chinese Taipei

Digital Learning Catalog

DIA Learning: eLearning Soultions

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.